An official american thoracic society clinical practice guideline

Diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease

Elizabeth S. Klings, Roberto Machado, Robyn J. Barst, Claudia R. Morris, Kamal K. Mubarak, Victor R. Gordeuk, Gregory J. Kato, Kenneth I. Ataga, J. Simon Gibbs, Oswaldo Castro, Erika B. Rosenzweig, Namita Sood, Lewis Hsu, Kevin C. Wilson, Marilyn J. Telen, Laura M. DeCastro, Lakshmanan Krishnamurti, Martin H. Steinberg, David B. Badesch, Mark T. Gladwin

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Background: In adults with sickle cell disease (SCD), an increased tricuspid regurgitant velocity (TRV) measured by Doppler echocardiography, an increased serum N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension (PH) diagnosed by right heart catheterization (RHC) are independent risk factors for mortality. Methods: A multidisciplinary committee was formed by clinicianinvestigators experienced in the management of patients with PH and/or SCD. Clinically important questions were posed, related evidence was appraised, and questions were answered with evidencebased recommendations. Target audiences include all clinicians who take care of patients with SCD. Results: Mortality risk stratification guides decision making. An increased risk formortality is defined as a TRVequal to or greater than 2.5m/second, anNT-pro-BNPlevel equal to or greater than 160 pg/ml, or RHC-confirmed PH. For patients identified as having increased mortality risk, we make a strong recommendation for hydroxyurea as first-line therapy and aweak recommendation for chronic transfusions as an alternative therapy. For all patients with SCD with elevated TRV alone or elevated NT-pro-BNP alone, and for patients with SCD with RHC-confirmed PH with elevated pulmonary artery wedge pressure and low pulmonary vascular resistance, we make a strong recommendation against PAH-specific therapy. However, for select patients with SCD with RHC-confirmed PH who have elevated pulmonary vascular resistance and normal pulmonary capillarywedge pressure, we make a weak recommendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong recommendation against phosphodiesterase-5 inhibitor therapy. Conclusions: Evidence-based recommendations for the management of patients with SCD with increased mortality risk are provided, but will require frequent reassessment and updating.

Original languageEnglish (US)
Pages (from-to)727-740
Number of pages14
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume189
Issue number6
DOIs
StatePublished - Mar 15 2014
Externally publishedYes

Fingerprint

Risk Management
Sickle Cell Anemia
Practice Guidelines
Pulmonary Hypertension
Thorax
Cardiac Catheterization
Mortality
Brain Natriuretic Peptide
Vascular Resistance
Epoprostenol Receptors
Phosphodiesterase 5 Inhibitors
Pulmonary Wedge Pressure
Hydroxyurea
Doppler Echocardiography
Therapeutics
Complementary Therapies
Decision Making
Patient Care
Pressure
Lung

Keywords

  • Dyspnea
  • Hemolysis
  • Mortality
  • Pulmonary hypertension
  • Sickle cell disease

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

An official american thoracic society clinical practice guideline : Diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. / Klings, Elizabeth S.; Machado, Roberto; Barst, Robyn J.; Morris, Claudia R.; Mubarak, Kamal K.; Gordeuk, Victor R.; Kato, Gregory J.; Ataga, Kenneth I.; Gibbs, J. Simon; Castro, Oswaldo; Rosenzweig, Erika B.; Sood, Namita; Hsu, Lewis; Wilson, Kevin C.; Telen, Marilyn J.; DeCastro, Laura M.; Krishnamurti, Lakshmanan; Steinberg, Martin H.; Badesch, David B.; Gladwin, Mark T.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 189, No. 6, 15.03.2014, p. 727-740.

Research output: Contribution to journalArticle

Klings, ES, Machado, R, Barst, RJ, Morris, CR, Mubarak, KK, Gordeuk, VR, Kato, GJ, Ataga, KI, Gibbs, JS, Castro, O, Rosenzweig, EB, Sood, N, Hsu, L, Wilson, KC, Telen, MJ, DeCastro, LM, Krishnamurti, L, Steinberg, MH, Badesch, DB & Gladwin, MT 2014, 'An official american thoracic society clinical practice guideline: Diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease', American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 6, pp. 727-740. https://doi.org/10.1164/rccm.201401-0065ST
Klings, Elizabeth S. ; Machado, Roberto ; Barst, Robyn J. ; Morris, Claudia R. ; Mubarak, Kamal K. ; Gordeuk, Victor R. ; Kato, Gregory J. ; Ataga, Kenneth I. ; Gibbs, J. Simon ; Castro, Oswaldo ; Rosenzweig, Erika B. ; Sood, Namita ; Hsu, Lewis ; Wilson, Kevin C. ; Telen, Marilyn J. ; DeCastro, Laura M. ; Krishnamurti, Lakshmanan ; Steinberg, Martin H. ; Badesch, David B. ; Gladwin, Mark T. / An official american thoracic society clinical practice guideline : Diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. In: American Journal of Respiratory and Critical Care Medicine. 2014 ; Vol. 189, No. 6. pp. 727-740.
@article{3b02c0978806498faf11febeae474c87,
title = "An official american thoracic society clinical practice guideline: Diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease",
abstract = "Background: In adults with sickle cell disease (SCD), an increased tricuspid regurgitant velocity (TRV) measured by Doppler echocardiography, an increased serum N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension (PH) diagnosed by right heart catheterization (RHC) are independent risk factors for mortality. Methods: A multidisciplinary committee was formed by clinicianinvestigators experienced in the management of patients with PH and/or SCD. Clinically important questions were posed, related evidence was appraised, and questions were answered with evidencebased recommendations. Target audiences include all clinicians who take care of patients with SCD. Results: Mortality risk stratification guides decision making. An increased risk formortality is defined as a TRVequal to or greater than 2.5m/second, anNT-pro-BNPlevel equal to or greater than 160 pg/ml, or RHC-confirmed PH. For patients identified as having increased mortality risk, we make a strong recommendation for hydroxyurea as first-line therapy and aweak recommendation for chronic transfusions as an alternative therapy. For all patients with SCD with elevated TRV alone or elevated NT-pro-BNP alone, and for patients with SCD with RHC-confirmed PH with elevated pulmonary artery wedge pressure and low pulmonary vascular resistance, we make a strong recommendation against PAH-specific therapy. However, for select patients with SCD with RHC-confirmed PH who have elevated pulmonary vascular resistance and normal pulmonary capillarywedge pressure, we make a weak recommendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong recommendation against phosphodiesterase-5 inhibitor therapy. Conclusions: Evidence-based recommendations for the management of patients with SCD with increased mortality risk are provided, but will require frequent reassessment and updating.",
keywords = "Dyspnea, Hemolysis, Mortality, Pulmonary hypertension, Sickle cell disease",
author = "Klings, {Elizabeth S.} and Roberto Machado and Barst, {Robyn J.} and Morris, {Claudia R.} and Mubarak, {Kamal K.} and Gordeuk, {Victor R.} and Kato, {Gregory J.} and Ataga, {Kenneth I.} and Gibbs, {J. Simon} and Oswaldo Castro and Rosenzweig, {Erika B.} and Namita Sood and Lewis Hsu and Wilson, {Kevin C.} and Telen, {Marilyn J.} and DeCastro, {Laura M.} and Lakshmanan Krishnamurti and Steinberg, {Martin H.} and Badesch, {David B.} and Gladwin, {Mark T.}",
year = "2014",
month = "3",
day = "15",
doi = "10.1164/rccm.201401-0065ST",
language = "English (US)",
volume = "189",
pages = "727--740",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - An official american thoracic society clinical practice guideline

T2 - Diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease

AU - Klings, Elizabeth S.

AU - Machado, Roberto

AU - Barst, Robyn J.

AU - Morris, Claudia R.

AU - Mubarak, Kamal K.

AU - Gordeuk, Victor R.

AU - Kato, Gregory J.

AU - Ataga, Kenneth I.

AU - Gibbs, J. Simon

AU - Castro, Oswaldo

AU - Rosenzweig, Erika B.

AU - Sood, Namita

AU - Hsu, Lewis

AU - Wilson, Kevin C.

AU - Telen, Marilyn J.

AU - DeCastro, Laura M.

AU - Krishnamurti, Lakshmanan

AU - Steinberg, Martin H.

AU - Badesch, David B.

AU - Gladwin, Mark T.

PY - 2014/3/15

Y1 - 2014/3/15

N2 - Background: In adults with sickle cell disease (SCD), an increased tricuspid regurgitant velocity (TRV) measured by Doppler echocardiography, an increased serum N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension (PH) diagnosed by right heart catheterization (RHC) are independent risk factors for mortality. Methods: A multidisciplinary committee was formed by clinicianinvestigators experienced in the management of patients with PH and/or SCD. Clinically important questions were posed, related evidence was appraised, and questions were answered with evidencebased recommendations. Target audiences include all clinicians who take care of patients with SCD. Results: Mortality risk stratification guides decision making. An increased risk formortality is defined as a TRVequal to or greater than 2.5m/second, anNT-pro-BNPlevel equal to or greater than 160 pg/ml, or RHC-confirmed PH. For patients identified as having increased mortality risk, we make a strong recommendation for hydroxyurea as first-line therapy and aweak recommendation for chronic transfusions as an alternative therapy. For all patients with SCD with elevated TRV alone or elevated NT-pro-BNP alone, and for patients with SCD with RHC-confirmed PH with elevated pulmonary artery wedge pressure and low pulmonary vascular resistance, we make a strong recommendation against PAH-specific therapy. However, for select patients with SCD with RHC-confirmed PH who have elevated pulmonary vascular resistance and normal pulmonary capillarywedge pressure, we make a weak recommendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong recommendation against phosphodiesterase-5 inhibitor therapy. Conclusions: Evidence-based recommendations for the management of patients with SCD with increased mortality risk are provided, but will require frequent reassessment and updating.

AB - Background: In adults with sickle cell disease (SCD), an increased tricuspid regurgitant velocity (TRV) measured by Doppler echocardiography, an increased serum N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension (PH) diagnosed by right heart catheterization (RHC) are independent risk factors for mortality. Methods: A multidisciplinary committee was formed by clinicianinvestigators experienced in the management of patients with PH and/or SCD. Clinically important questions were posed, related evidence was appraised, and questions were answered with evidencebased recommendations. Target audiences include all clinicians who take care of patients with SCD. Results: Mortality risk stratification guides decision making. An increased risk formortality is defined as a TRVequal to or greater than 2.5m/second, anNT-pro-BNPlevel equal to or greater than 160 pg/ml, or RHC-confirmed PH. For patients identified as having increased mortality risk, we make a strong recommendation for hydroxyurea as first-line therapy and aweak recommendation for chronic transfusions as an alternative therapy. For all patients with SCD with elevated TRV alone or elevated NT-pro-BNP alone, and for patients with SCD with RHC-confirmed PH with elevated pulmonary artery wedge pressure and low pulmonary vascular resistance, we make a strong recommendation against PAH-specific therapy. However, for select patients with SCD with RHC-confirmed PH who have elevated pulmonary vascular resistance and normal pulmonary capillarywedge pressure, we make a weak recommendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong recommendation against phosphodiesterase-5 inhibitor therapy. Conclusions: Evidence-based recommendations for the management of patients with SCD with increased mortality risk are provided, but will require frequent reassessment and updating.

KW - Dyspnea

KW - Hemolysis

KW - Mortality

KW - Pulmonary hypertension

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84896501856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896501856&partnerID=8YFLogxK

U2 - 10.1164/rccm.201401-0065ST

DO - 10.1164/rccm.201401-0065ST

M3 - Article

VL - 189

SP - 727

EP - 740

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -